BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04814108 (ZN-c3 in Uterine Serous Carcinoma): BVCT ex-ante prediction vs. reported outcome

On 25 May 2023, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 18 Jun 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04814108
Acronym
TETON
Drug Name
ZN-c3
Drug MoA
Wee1 inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Uterine Serous Carcinoma
Human Patients
76
Sponsor
Zentalis Pharmaceuticals
Phase
Phase 2

Prediction of , index 1079

Prospective Prediction
Prediction Index
1079
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit regardless of CCNE1 expression)
Technical Prediction
FAILURE (statistically insignificant clinical efficacy in ORR in placebo-controlled trial and moderate clinical toxicity)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
390 days in advance
Readout Data Interpretation
high toxicity resulting in clinical hold.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma
Phase
Phase 2
Status
Completed
Enrollment
92
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Conditions
Uterine Serous Carcinoma
Interventions
DRUG: Azenosertib
Design
Single group · None
Primary purpose
Treatment
Start
2021-07-28
Primary completion
2025-10-22
Completion
2025-10-22
Primary outcomes
  • Frequency and severity of TEAEs (2 years)
  • Objective Response Rate as defined by the revised RECIST v1.1 as assessed by ICR (2 years)

NCT04814108 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials